Name: Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS (Video) | JoVE Journal
Uploaded: 2015-11-08T14:00:00.000+00:00
Duration: 8 min 38 s
Description: Learn to quantify tacrolimus in dried blood spots using HPLC-MS/MS for therapeutic drug monitoring. This minimally invasive method enables patient self-collection and supports accurate immunosuppressant analysis.

ai_agent_IP

ai_agent

maintenance

instantTrialDurationMinutes

isBiopharma

enableNewMyJoveSectionDesign

educationFeatures

seoMetaApi

ai_copilot_institution_blacklist

ai_chat_institution_blacklist

freeAccessWindow

ssoRoleCapture

scheduledMaintenanceBanner

joveLabsFeatures

disable_autoplay_for_bots

extended_trial_duration

5 minutes

This work was supported by the United States Federal Drug Administration (FDA) contract HHSF223201310224C and the United States National Institutes of Health/FDA grant 1U01FD004573-01.

De-identified blood samples from healthy individuals were from the University of Colorado Hospital (Aurora, Colorado). The use of de-identified blood bank samples for validation studies as well as for the preparation of calibrators and quality control samples was considered &#8220;exempt&#8221; by the Colorado Multi-institutional Review Board (COMIRB, Aurora, Colorado).
1. Preparation of References and Solutions
<ol>
	<li>Purchase tacrolimus and the internal standard D2,13C-tacrolimus from the vendors listed in the Materials List.
	<ol>
		<li>Prepare stock solutions in pure methanol at a concentration of 1 mg/ml for tacrolimus and a concentration of 10 &#181;g/ml for D2,13C-tacrolimus. Make stock solutions of reference materials based on three independent weightings. Aliquot stock solutions and store at -70 &#176;C or below.</li>
	</ol>
	</li>
	<li>Prepare solution to precipitate proteins and extract tacrolimus using methanol / 0.2 M ZnSO4 in water (7:3, v:v). This solution also contains the internal standard D2,13C-tacrolimus at a concentration of 2.5 ng/ml and is used for the extraction of all samples except for the extraction of blank samples (please see 1.3.3).
	<ol>
		<li>Prepare this protein precipitation solution freshly on each extraction day and set the expiration of the solution at 12 hr.</li>
	</ol>
	</li>
	<li>Preparation of calibration curve and quality control (QC) samples
	<ol>
		<li>Prepare stock solutions of tacrolimus by performing appropriate dilutions of the stock solution using pure methanol.</li>
		<li>To prepare calibrators and quality control samples, spike 20 &#181;l of appropriately diluted stock solution into EDTA whole blood, incubate at 37 &#176;C under gentle shaking in a water bath to allow for homogeneous distribution of tacrolimus into the cellular blood components for 20 min and aliquot into 1.5 ml polypropylene tubes with conical bottom and snap-on lids. Ensure that the relative volume of organic solvent does not exceed 5%.</li>
		<li>Spot 50 &#181;l of the spiked whole blood into the middle of each circle on the filter cards using a pipette.</li>
		<li>Dry the blood spots on filter cards at RT for 3 hr.</li>
		<li>Prepare tacrolimus calibration standards in human EDTA whole blood at tacrolimus concentrations of 1, 2.5, 5, 10, 25, and 50 ng/ml. Prepare a blank sample for extraction like the calibration standards with the protein precipitation solution containing the internal standard D2,13C-tacrolimus (&#8220;zero sample&#8221;).</li>
		<li>Prepare QC samples in human EDTA whole blood at concentrations of 0, 2, 4, 20, 40 ng/ml. Prepare a blank sample. In contrast to the QC samples that are extracted with precipitation containing the internal standard D2,13C-tacrolimus, extract this blank sample with protein precipitation solution that does not contain the internal standard D2,13C-tacrolimus (&#8220;blank sample&#8221;).</li>
	</ol>
	</li>
	<li>Collection of clinical samples
	<ol>
		<li>Collect dried blood spots as described in43,44.</li>
	</ol>
	</li>
</ol>
2. Extraction of Tacrolimus Dried Blood Spot Samples
<ol>
	<li>Visually inspect the dried blood spot to ensure acceptable sample quality and volume45.</li>
	<li>Punch center of the blood spot on the filter card with a 6-mm hole punch. 
	Note: The quality of punches may be monitored by weighing. A punched saturated filter disc weighs in average 5.02 mg &#177; 0.09 mg (range: 4.83- 5.14 mg, n=12).</li>
	<li>Place discs into 1.5 ml polypropylene tubes with conical bottom and snap-on lids.</li>
	<li>Add 20-30 bullets to each tube.</li>
	<li>Add 500 &#181;l of the protein precipitation solution (methanol: 0.2 M ZnSO4, 7:3, v:v with 2.5 ng/ml internal standard) into each tube. For the extraction of blank samples, use protein precipitation solution without the internal standard.</li>
	<li>Homogenize the discs in the bullet blender for 1 min (maximum speed, setting &#8220;10&#8221;).</li>
	<li>Shake samples at RT on multi-tube vortex (maximum speed, setting &#8220;10&#8221;) for 10 min.</li>
	<li>Centrifuge samples at 16,000 x g and 4 &#176;C for 10 min.</li>
	<li>Transfer the supernatants into glass HPLC vials equipped with a 300 &#181;l insert. Use pre-slit Teflon seals. 
	Note: Extracted samples may be stored at -20 &#176;C or below until LC-MS/MS analysis.</li>
</ol>
3. LC-MS/MS Analysis
<ol>
	<li>Load 100 &#181;l of the supernatant of the extracted sample onto the C8 cartridge extraction column and wash with a 7:3 ratio of 0.1% formic acid in water: acetonitrile at a flow of 5 ml/min for 1 min. The connections of the switching valve are shown in Figure 2 and the gradient run by the extraction pump in Table 1.</li>
	<li>Hereafter, activate the switching valve resulting in back-flush of the analytes from the pre-column onto the analytical column.</li>
	<li>Set the column thermostat to 65 &#176;C.</li>
	<li>Elute the analytes from the analytical column using the flow rates and gradient shown in Table 1.</li>
	<li>Connect the analytical column to a tandem mass spectrometer via the turbo electrospray ionization source. Adjust the key parameters of the mass spectrometer according to Table 2.</li>
	<li>Detect positive ions ([M+Na]+) in the multiple reaction mode (MRM). Use the following ion transitions for quantification: tacrolimus: m/z (mass/charge) = 826.6 &#8594; 616.2 and D2,13C-tacrolimus: m/z= 829.6 &#8594; 619.2. 
	Note: The total run time is 4.6 min.</li>
</ol>
4. Quantification
<ol>
	<li>For each run, generate a calibration curve based on the calibrators prepared in 1.3.5 and include in each analytical run.
	<ol>
		<li>Generate a calibration curve by plotting nominal concentrations versus response factor of analyte (Peak Area [Analyte] / Peak Area [internal standard]) using the mass spectrometer software.</li>
		<li>Fit the calibrators using a quadratic fit in combination with 1/X weighting.</li>
	</ol>
	</li>
	<li>To quantity tacrolimus in the dried blood spots integrate the tacrolimus and internal standard peaks in the extracted MRM chromatograms. Calculate the response factor for tacrolimus (Peak Area [Analyte] / Peak Area [internal standard]) and compare with the calibration curve using the mass spectrometry software.</li>
</ol>
5. Validation Procedures
<ol>
	<li>Lower limit of detection (LLOD) and lower limit of quantification (LLOQ).
	<ol>
		<li>Consider the lowest tacrolimus concentration with a peak-to-noise ratio of 4:1 as the lower limit of detection (LLOD). Define the lower limit of quantification (LLOQ) as the lowest concentration of the calibration curve with an accuracy equal to or better than &#177; 20% deviation from the nominal concentration and precision equal to or better than 20% (coefficient of variance).</li>
	</ol>
	</li>
	<li>Intra- and inter-day accuracies and precisions.
	<ol>
		<li>Test the accuracy and precision at four concentration levels of 2 ng/ml (QC1), 4 ng/ml (QC2), 20 ng/ml (QC3) and 40 ng/ml (QC4).</li>
		<li>Prepare the QC samples on each validation day in human EDTA whole blood, dry on filter cards, extract, and analyze as described above.</li>
		<li>Determine intra-day accuracy and precision with 6 samples per QC concentration level.</li>
		<li>Assess inter-day accuracy and precision over 20 days. Measure each QC level with 4 samples each day.</li>
		<li>Analyze two calibration curves together with the QC samples on each day.</li>
		<li>Calculate intra-day accuracy as the % of the nominal concentration (six samples per concentration level, please see 5.2.2). Calculate precision as the coefficient of variance (CV%).</li>
		<li>Consider intra-day accuracy acceptable if it falls into the acceptance limits 85% to 115% of the nominal concentration. Consider intra-day precision acceptable if it is equal to or better than a CV (coefficient of variance) of 15%.</li>
		<li>Calculate inter-day accuracy and precision as the mean for each QC concentration level analyzed over the 20 validation days.</li>
		<li>Consider mean inter-day accuracy acceptable if it falls into the acceptance limits 85% to 115% of the nominal concentration. Consider inter-day precision acceptable if it is equal to or better than a CV (coefficient of variance) of 15%.</li>
	</ol>
	</li>
	<li>Exclusion of matrix interferences.
	<ol>
		<li>For the exclusion of interferences that may be caused by matrix signals, analyze blank dried blood spots (8 different individuals, preferably 4 males and 4 females).</li>
		<li>Visually inspect ion chromatograms. If peaks within the retention time window of tacrolimus are detected, integrate and compare their areas under the curve with those of tacrolimus peaks in blank samples spiked with tacrolimus at the LLOQ. The area of peaks in the blank samples are not supposed to exceed 15% of those of tacrolimus at the LLOQ.</li>
	</ol>
	</li>
	<li>Ion suppression/ion enhancement.
	<ol>
		<li>Use a post-column infusion protocol as described45 to assess potential interference of ion suppression/ion enhancement caused by co-eluting matrix components.</li>
		<li>Infuse tacrolimus at a concentration of 10 &#181;g/ml dissolved in 0.1% formic acid: methanol (30:70, v/v) post-column at a rate of 10 &#181;l/min.
		<ol>
			<li>Connect a syringe pump via T-piece between the analytical column and the electrospray source of the mass spectrometer.</li>
			<li>Monitor the MS/MS signal intensity of the MRM transitions for tacrolimus and its internal standard (m/z = 826.6 &#8594; 616.2 and m/z = 829.6 &#8594; 619.2) after injection of extracted blank samples (n = 8 samples from different individuals). 
			Note: In the absence of ion suppression/ion enhancement the continuous signal caused by infusion of the analytes should not be affected by injection of the blank matrix, while ion suppression causes a dip of the signal and ion enhancement a peak.</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>Carry-over.
	<ol>
		<li>Assess potential carry-over by analyzing extracted blank samples after the highest calibrators (50 ng/ml, n = 6).</li>
		<li>Visually inspect ion chromatograms. If peaks within the retention time window of tacrolimus are detected, integrate and compare their areas under the curve with those of tacrolimus peaks in blank samples spiked with tacrolimus at the LLOQ. The area of peaks in the blank samples are not supposed to exceed 15% of those of tacrolimus at the LLOQ.</li>
	</ol>
	</li>
	<li>Extraction recoveries.
	<ol>
		<li>Determine recoveries by comparing the signals of the analytes after extraction of QC samples at all four concentration levels (n = 6 per concentration) with those of blank dried blood spots spiked with the corresponding amounts of tacrolimus after the extraction.</li>
		<li>Prepare four sets of QCs (concentration levels: 2, 4, 20, 40 ng/ml).</li>
		<li>Prepare another 4 sets of corresponding &#8220;recovery test samples&#8221; by spotting 50 &#181;l of blank EDTA whole blood onto the filter paper cards and drying for 2 hr.</li>
		<li>Hereafter, for both the QC and blank &#8220;recovery test samples&#8221;, cut out the entire blood spot on the filter card with scissors and place the resulting discs into a polypropylene tube with conical bottom and snap-on lid.</li>
		<li>Extract all samples.</li>
		<li>Transfer the supernatants (400 &#181;l) into glass HPLC vials.</li>
		<li>Add tacrolimus stock solution to the blank &#8220;extracted recovery test samples&#8221; to reach concentrations of 2, 4, 20 and 40 ng/ml (4 &#181;l of 200, 400, 2,000, 4,000 ng/ml tacrolimus stock solutions to 400 &#181;l of supernatant).</li>
		<li>After LC-MS/MS analysis, compare the signals in both QC samples and &#8220;recovery test samples&#8221; of the corresponding concentration (recovery% = signal samples spiked before extraction / signal samples spiked after extraction x 100).</li>
	</ol>
	</li>
	<li>Dilution integrity.
	<ol>
		<li>Establish dilution integrity using samples spiked with the analytes at 500, 250 and 100 ng/ml.</li>
		<li>After extraction, dilute samples using protein precipitation solution (1:10, n = 3 per concentration level).</li>
		<li>Calculate deviations from the nominal concentrations. Consider results that fall within 85%-115% of nominal acceptable.</li>
	</ol>
	</li>
	<li>Stabilities.
	<ol>
		<li>Investigate stabilities using the QC samples at all four concentration levels (n = 4 per concentration) analyzed at different time-points and under the different storage conditions.</li>
		<li>Compare results after storage with the nominal values. Consider results that fall within 85%-115% of nominal acceptable.</li>
		<li>Establish sample stability for 1 week at ambient temperature, 1 week at 4 &#176;C, 1 month at -20 &#176;C and 1 month at -80 &#176;C.</li>
		<li>Test freeze-thaw stability over three cycles (-20 &#176;C). Test extracted sample and autosampler stability by placing samples into the thermostatted autosampler adjusted to 4 &#176;C. Inject samples after 72 hr.</li>
	</ol>
	</li>
</ol>

The authors have nothing to disclose.

Although, as aforementioned, the concept of therapeutic drug and adherence monitoring of tacrolimus based on dried blood spots is attractive, there are analytical challenges that go beyond those typically associated with the LC-MS/MS analysis of tacrolimus in venous EDTA whole blood samples. These include, but are not limited to, the fact that the matrix is capillary whole blood soaked into the cotton linters material of the filter card material used here and the low blood volume (20 &#181;l). Nevertheless, high-throughp...

Tacrolimus is a potent immonosuppressant1-7 that has a macrolide structure8 (Figure 1). Due to cis-trans isomerism of the C-N bonds it forms two rotamers in solution9 that can be separated by reversed phase high-performance liquid chromatography (HPLC) Tacrolimus is lipophilic and soluble in alcohols (methanol: 653 g/L, ethanol: 355 g/L), halogenated hydrocarbons (chloroform: 573 g/L) and ether. It is sparingly soluble in aliphatic hydrocarbons (hexane: 0.1 g/L and water (pH 3: 0.0047 g/L)9. The molecule does not contain any chromophore and its UV-absorption maximum is 192 nm. Tacrolimus acts via inhibition of calcineurin. Its mechanism of action has been reviewed in references10,11. It is currently used in more than 80% of solid-organ transplant patients in the United States12.
The therapeutic index of tacrolimus is considered to be narrow13. In addition, the correlation between tacrolimus doses and blood concentrations is poor and pharmacokinetics is variable14,15. Therapeutic drug monitoring to guide tacrolimus dosing in transplant patients is therefore general clinical practice16-20. The goal is to keep the tacrolimus blood concentrations within a pre-defined therapeutic range. Tacrolimus blood concentrations below the therapeutic range may result in increased activity of chronic or acute allo-immune reactions, while concentrations above the therapeutic window increase the risk for over-immunosuppression, cancer and toxicities, such as nephrotoxicity, neurotoxicity, hypertension, and diabetes. High pharmacokinetic intra-individual variability of tacrolimus may be detrimental to both transplant organ and patient survival21,22. While inter-individual variability of tacrolimus pharmacokinetics is mainly caused by CYP3A5 polymorphisms, reasons for intra-individual variability include, but are not limited to, drug-drug, disease-drug and food-drug interactions14,15. Also lack of adherence to the immunosuppressive therapeutic drug regimen is a contributing factor and a major reason for graft loss23,24.
These considerations suggest that frequent home therapeutic drug and adherence monitoring of tacrolimus whole blood concentrations may be beneficial to ensure that patients have tacrolimus exposure within the desired therapeutic window at all times. However, the logistics and cost of more frequent therapeutic drug monitoring as it is current clinical practice15 is prohibitive. One of the reasons is that the patient has to see a phlebotomist to have the required venous blood sample drawn. Dried blood spots have recently emerged as an attractive concept25-28. After a simple finger stick the patient collects a blood drop on a special filter paper card and after the blood spot has dried, it can be mailed to a central laboratory for analysis of tacrolimus and any other immunosuppressant that the patient may currently be taking. This has become possible due to the development of highly sensitive and specific LC-MS/MS assays for the quantification of tacrolimus and other immunosuppressants in very small blood volumes such as dried blood spots (typically 20 &#181;l of blood)25,29-43. Another advantage is that minimally invasive, low volume sample collection strategies such as dried blood spots greatly facilitate therapeutic drug monitoring and pharmacokinetic studies in small children28.
Tacrolimus is usually measured in venous EDTA whole blood15. Reasons are that tacrolimus extensively distributes into blood cells and that clinical studies have reported better correlation between tacrolimus trough concentrations in blood than in plasma with clinical events15,18. In comparison, the analysis of tacrolimus in dried blood spots is based on capillary blood that is mixed with the filter paper matrix. This presents challenges in terms of solubilization of tacrolimus and potential interferences with the LC-MS/MS analysis. Here we present an established and validated assay based on homogenization of the dried blood spot using a bullet blender in combination with a high-flow online column sample clean up procedure and LC-MS/MS analysis. As of today, this assay has successfully been used for the quantification of more than five thousand tacrolimus dried blood spot samples for adherence monitoring in clinical trials.

<table><tbody><tr><td>Tacrolimus</td><td>U.S. Pharmacopeial Convention</td><td>1642802</td><td></td></tr><tr><td>D&lt;sub&gt;2&lt;/sub&gt;,&lt;sup&gt;13&lt;/sup&gt;C-Tacrolimus</td><td>Toronto Research Chemicals Inc.</td><td>F370002</td><td></td></tr><tr><td>Red blood cells</td><td>University of Colorado Hospital</td><td>W20091305500 V</td><td></td></tr><tr><td>Plasma</td><td>University of Colorado Hospital</td><td>W2017130556300Q</td><td></td></tr><tr><td>Acetone CHROMASOLV, HPLC, &amp;ge;99,9%</td><td>Sigma-Aldrich</td><td>439126-4 L</td><td></td></tr><tr><td>Acetonitrile Optima LC/MS, UHPLC-UV</td><td>Thermo Fisher Scientific</td><td>A955-4</td><td></td></tr><tr><td>Isopropanol 99.9%, HPLC</td><td>Fisher Scientific</td><td>BP2632-4</td><td></td></tr><tr><td>Methanol Optima LC/MS</td><td>Thermo Fisher Scientific</td><td>A452-4</td><td></td></tr><tr><td>Water Optima LC/MS, UHPLC-UV</td><td>Thermo Fisher Scientific</td><td>W6-4</td><td></td></tr><tr><td>Formic acid</td><td>Thermo Fisher Scientific</td><td>A118P-500</td><td></td></tr><tr><td>Phosphate-buffered saline (PBS)</td><td>Sigma-Aldrich</td><td>D8537</td><td></td></tr><tr><td>Zinc sulfate</td><td>Thermo Fisher Scientific</td><td>Z68-500</td><td></td></tr><tr><td>0.5 &amp;ndash; 10 &amp;micro;l pipet, VoluMate LIQUISYSTEMS</td><td>Mettler Toledo</td><td>17008649</td><td></td></tr><tr><td>1.5 ml Eppendorf tube</td><td>Thermo Fisher Scientific</td><td>02-682-550</td><td></td></tr><tr><td>10 &amp;ndash; 100 &amp;micro;l pipet, VoluMate LIQUISYSTEMS</td><td>Mettler Toledo</td><td>17008651</td><td></td></tr><tr><td>10 &amp;mu;l pipet tips with filter, sterile</td><td>Neptune</td><td>BT 10XLS3</td><td></td></tr><tr><td>100 &amp;ndash; 1,000 &amp;micro;l pipet, VoluMate LIQUISYSTEMS</td><td>Mettler Toledo</td><td>17008653</td><td></td></tr><tr><td>100 &amp;mu;l pipet tips with filter, sterile</td><td>Neptune</td><td>BT 100</td><td></td></tr><tr><td>1,000 &amp;mu;l pipet tips with filter, sterile</td><td>Multimax</td><td>2940</td><td></td></tr><tr><td>2 &amp;ndash; 20 &amp;micro;l pipet, VoluMate LIQUISYSTEMS</td><td>Mettler Toledo</td><td>17008650</td><td></td></tr><tr><td>2 ml Eppendorf tube</td><td>Thermo Fisher Scientific</td><td>02-681-258</td><td></td></tr><tr><td>20 &amp;ndash; 200 &amp;micro;l pipet, VoluMate LIQUISYSTEMS</td><td>Mettler Toledo</td><td>17008652</td><td></td></tr><tr><td>20 &amp;mu;l pipet tips with filter, sterile</td><td>GeneMate</td><td>P-1237-20</td><td></td></tr><tr><td>200 &amp;mu;l pipet tips with filter</td><td>Multimax</td><td>2938T</td><td></td></tr><tr><td>200 &amp;mu;l pipet tips with filter, sterile</td><td>Multimax</td><td>2936J</td><td></td></tr><tr><td>50 ml Falcon tube</td><td>BD Falcon</td><td>352070</td><td></td></tr><tr><td>300 &amp;mu;l inserts for HPLC vials</td><td>Phenomenex</td><td>ARO-9973-13</td><td></td></tr><tr><td>Balance PR2002</td><td>Mettler Toledo</td><td>1117050723</td><td></td></tr><tr><td>Balances AX205 Delta Range</td><td>Mettler Toledo</td><td>1119343379</td><td></td></tr><tr><td>Bullet Blender Homogenizer</td><td>Next Advance</td><td>BBX24</td><td></td></tr><tr><td>Centrifuge Biofuge Fresco</td><td>Heraeus</td><td>290395</td><td></td></tr><tr><td>Disposable Wipes</td><td>PDI</td><td>Q55172</td><td></td></tr><tr><td>Glass v ials, 4 ml</td><td>Thermo Fisher Scientific</td><td>14-955-334</td><td></td></tr><tr><td>Glass vials, 20 ml</td><td>Thermo Fisher Scientific</td><td>B7800-20</td><td></td></tr><tr><td>Gloves, nitrile</td><td>Titan Brand Gloves</td><td>44-100S</td><td></td></tr><tr><td>HPLC vials, 9 mm, 2 ml, clear</td><td>Phenomenex</td><td>ARO- 9921-13</td><td></td></tr><tr><td>Lids for HPLC vials</td><td>Phenomenex</td><td>ARO- 8952-13-B</td><td></td></tr><tr><td>Needle, 18 G 1.5</td><td>Precision Glide</td><td>305196</td><td></td></tr><tr><td>Rack for Eppendorf tubes</td><td>Thermo Fisher Scientific</td><td>03-448-11</td><td></td></tr><tr><td>Rack for HPLC Vials</td><td>Thermo Fisher Scientific</td><td>05-541-29</td><td></td></tr><tr><td>Steel beads 0.9 &amp;ndash; 2 mm</td><td>Next Advance</td><td>SSB14B</td><td></td></tr><tr><td>Storage boxes for freezers / refrigerators</td><td>Thermo Fisher Scientific</td><td>03-395-464</td><td></td></tr><tr><td>Standard multi-tube vortexer</td><td>VWR Scientific Products</td><td>658816-115</td><td></td></tr><tr><td>Whatman Paper, 903 Protein Saver US 100/PK</td><td>GE Whatman&amp;nbsp;</td><td>2016-05</td><td></td></tr><tr><td>Autosampler</td><td>CTC PAL&amp;nbsp;</td><td>PAL.HTCABIx1</td><td></td></tr><tr><td>Binary pump, Agilent 1260 Infinity</td><td>Agilent Technologies</td><td>1260 G1312B</td><td></td></tr><tr><td>Binary pump, Agilent 1290 Infinity</td><td>Agilent Technologies</td><td>1290 G4220A</td><td></td></tr><tr><td>Micro vacuum degasser, Agilent 1260</td><td>Agilent Technologies</td><td>1260 G13798</td><td></td></tr><tr><td>Column oven,&amp;nbsp; Agilent 1290 with 2 position&amp;nbsp;</td><td>Agilent Technologies</td><td>1290 G1216C</td><td></td></tr><tr><td>Thermostated column compartment with integrated 6 port switching valve</td><td>Agilent Technologies</td><td>1290 G1316C</td><td></td></tr><tr><td>HPLC pre-column cartridge, Zorbax XDB C8 (5 &amp;micro;m particle size), 4.6 &amp;middot; 12.5 mm</td><td>Phenomenex</td><td>820950-926</td><td></td></tr><tr><td>HPLC analytical column, Zorbax Eclipse-XDB-C8 (5 &amp;micro;m particle size), 4.6 &amp;middot; 150 mm</td><td>Phenomenex</td><td>993967-906</td><td></td></tr><tr><td>Tandem Mass Spectrometer</td><td></td><td></td><td></td></tr><tr><td>API5000 MS/MS with TurboIonspray source</td><td>AB Sciex</td><td>4364257</td><td></td></tr><tr><td>Mass spectrometry software</td><td>AB Sciex</td><td>Analyst 1.5.1</td><td></td></tr></tbody></table>

quantification of the immunosuppressant tacrolimus on dried blood spots using lc-ms/ms

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

The calcineurin inhibitor tacrolimus is the cornerstone of most immunosuppressive treatment protocols after solid organ transplantation in the United States. Tacrolimus is a narrow therapeutic index drug and as such requires therapeutic drug monitoring and dose adjustment based on its whole blood trough concentrations. To facilitate home therapeutic drug and adherence monitoring, the collection of dried blood spots is an attractive concept. After a finger stick, the patient collects a blood drop on filter paper at home. After the blood is dried, it is mailed to the analytical laboratory where tacrolimus is quantified using high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) in combination with a simple manual protein precipitation step and online column extraction.
For tacrolimus analysis, a 6-mm disc is punched from the saturated center of the blood spot. The blood spot is homogenized using a bullet blender and then proteins are precipitated with methanol/0.2 M ZnSO4 containing the internal standard D2,13C-tacrolimus. After vortexing and centrifugation, 100 &#181;l of supernatant is injected into an online extraction column and washed with 5 ml/min of 0.1 formic acid/acetonitrile (7:3, v:v) for 1 min. Hereafter, the switching valve is activated and the analytes are back-flushed onto the analytical column (and separated using a 0.1% formic acid/acetonitrile gradient). Tacrolimus is quantified in the positive multi reaction mode (MRM) using a tandem mass spectrometer.
The assay is linear from 1 to 50 ng/ml. Inter-assay variability (3.6%-6.1%) and accuracy (91.7%-101.6%) as assessed over 20 days meet acceptance criteria. Average extraction recovery is 95.5%. There are no relevant carry-over, matrix interferences and matrix effects. Tacrolimus is stable in dried blood spots at RT and at +4 &#176;C for 1 week. Extracted samples in the autosampler are stable at +4 &#176;C for at least 72 hr.

Representative ion chromatograms of a blank sample, a sample spiked at the lower limit of quantification and a patient sample are shown in Figure 3.
Calibration Curves
The lower limit of detection was 0.5 ng/ml and the lower limit of quantification was 1.0 ng/ml. Fifty ng/ml was chosen as the highest calibrator as higher concentrations are unlikely to be reached in the clinic under normal circumstances.
Calibration curves...

Here we describe a high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay to quantify the immunosuppressant tacrolimus in dried blood spots using a simple manual protein precipitation step and online column extraction.

The calcineurin inhibitor tacrolimus is the cornerstone of most immunosuppressive treatment protocols after solid organ transplantation in the United ...

The overall goal of the following experiment is to quantify tacrolimus in dried blood spots. The main advantage of this technique over quantification of tacrolimus in blood samples after IV blood draw is that patients can collect samples themselves minimally invasive low volume sample collection strategies such as dried blood spots also facilitate therapeutic drug monitoring and pharmacokinetic studies in small children. After a simple finger stick, the patient collects a blood drop on a special filter paper card, and after the blood spot is dried, it can be mailed to a central laboratory for analysis of tacrolimus and any other immunosuppressant that the patient may be taking.Quantification of drugs on dried blood spots has become possible due to the development of highly sensitive and specific LCM SM S assays for the quantification of tacrolimus and other immunosuppressants in very small blood volumes such as dried blood spots. First, prepare stock solutions in pure methanol at a concentration of one milligram per milliliter for tacrolimus and a concentration of 10 micrograms per milliliter. For D two 13 C aliquot stock solutions and store at negative 70 degrees Celsius or below on each extraction day, prepare a seven to three ratio of methanol and 0.2 molar zinc sulfate in water to precipitate proteins and extract tacrolimus.The internal standard stock solution is spiked into the precipitation solution. Set the expiration of the solution at 12 hours. Following this, prepare stock solutions of tacrolimus by performing appropriate dilution of the stock solution using pure methanol to prepare calibrators and quality control samples.Spike 20 microliters of the appropriately diluted stock solution into EDT. A whole blood incubate at 37 degrees Celsius under gentle shaking in a water bath for 20 minutes to allow for homogeneous distribution of tacrolimus into the cellular blood components. To prepare a larger amount of calibrators and quality control samples spike 2000 microliters of the appropriately diluted stock solution into EDT.A whole blood incubate at 37 degrees Celsius under gentle shaking in a water bath for 20 minutes to allow for homogeneous distribution of tacrolimus into the cellular blood components. Then aliquot the samples into 1.5 milliliter polypropylene tubes with conical bottoms and snap-on lids. Spot 50 microliters of the spiked whole blood into the middle of each circle on filter cards using a pipette after drying the blood spots at room temperature for three hours, prepare tacrolimus calibration standards in human EDTA whole blood at tacrolimus concentrations of one 2.5 5, 10 25, and 50 nanograms per milliliter.Prepare a blank sample for extraction like the calibration standards with the protein precipitation solution, not containing the internal standard D two 13 C tacrolimus. Next, prepare quality control samples in human EDTA whole blood at concentrations of 0 2 4 20 and 40 nanograms per milliliter. Prepare a blank sample as well After collecting the dried blood spots, visually inspect each one to ensure acceptable sample quality and volume.Then punch the center of the blood spot on the filter card with a six millimeter hole punch. Place the discs into 1.5 milliliter polypropylene tubes with conical bottoms and snap on lids. Add 20 to 30 bullets to each tube.Following this, add 500 microliters of the protein precipitation solution into each tube. Homogenize the discs in a bullet blender for one minute at maximum speed. When finished, shake the samples at room temperature on a multi tube vortex at maximum speed for 10 minutes.Then centrifuge the samples at 16, 000 GS and four degrees Celsius for 10 minutes. After centrifugation, transfer the SNAT into glass HPLC vials equipped with a 300 microliter insert. At this point, load 100 microliters of the supernat of the extracted sample onto the C eight cartridge extraction column wash with a seven to three ratio of 0.1%formic acid in water and acid nitrile at a flow of five milliliters per minute.For one minute hereafter activate the switching valve resulting in back flush of the analytes from the pre-cal onto the analytical column. Then set the column thermostat to 65 degrees Celsius. Elute the analytes from the analytical column using the flow rates and gradient shown here.Connect the analytical column to a tandem mass spectrometer via the turbo electrospray ionization source. Adjust the key parameters of the mass spectrometer according to the following table. Next, detect positive ions in the multiple reaction mode.To quantify tacrolimus in the dried blood spots, compare it with the calibration curve using the mass spectrometry software representative ion chromatograms of a blank sample. A sample spiked at the lower limit of quantification and a patient sample are shown here. A typical calibration curve is shown here.The mean coefficient of correlation is 0.9994. The accuracy and precision results are shown in detail here. No indications of significant ion suppression or ion enhancement were observed and no relevant carryover resulting in peaks exceeding.15%of the signal at the lower limit of quantitation were detected. Dilution integrity was investigated by analyzing samples prepared at concentrations above the highest calibrator and diluted in protein precipitation solution after extraction to reach the target concentrations. All dilutions tested met acceptance criteria.No losses were apparent after one week of storage at room temperature after one week of storage at four degrees Celsius and after one month of storage at negative 20 degrees Celsius. In addition, no losses were observed after one month of storage at negative 80 degrees Celsius after three freeze and thaw cycles, and after 72 hours of extracted samples in the auto sampler at four degree Celsius. Once mastered 20 samples can be extracted in less than one hour.While attempting this procedure, it is important to remember that the key to reliable quantification is the quality of the dried blood spot and that the disc is punched from a completely saturated area of the filter paper. The techniques and the assay shown in this video provide a platform technology to quantify other immunosuppressants and drugs in dried blood spots.

quantification-immunosuppressant-tacrolimus-on-dried-blood-spots

Research

JoVE Journal

Medicine

Tregs are potent suppressors of the immune system. There is a lack of unique surface markers to define them, hence, definitions of Tregs are primarily functional. Here we describe an optimized in vitro assay capable of identifying immune imbalance in subjects at risk to develop T1D.

Human In Vitro Suppression as Screening Tool for the Recognition of an Early State of Immune Imbalance

We report a method for drug sorption evaluation using a pump and model drugs (diazepam and tacrolimus). After drug analysis using high-performance liquid chromatography, drug concentrations and sorption levels in the tubes of administration sets are calculated.

Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump

Here, we describe a chromatographic assay coupled with the ion mobility separation of peptide precursors followed by the high-resolution (~30,000) MS-detection of peptide fragments for the quantification of spiked peptide standards in a monoclonal antibody digest.

An HS-MRM Assay for the Quantification of Host-cell Proteins in Protein Biopharmaceuticals by Liquid Chromatography Ion Mobility QTOF Mass Spectrometry

Ivacaftor and ivacaftor-lumacaftor combination are two new CF drugs. However, there is still a dearth of understanding on their PK/PD and pharmacology. We present an optimized HPLC-MS technique for the simultaneous analysis of ivacaftor and its major metabolites, and lumacaftor.

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

This protocol describes a simple and useful method to store peripheral blood and serum/plasma for downstream analyses such as single nucleotide polymorphism (SNP) evaluation and ELISA assay.

Dried Blood and Serum Spots As A Useful Tool for Sample Storage to Evaluate Cancer Biomarkers

Here, we describe a protocol using laser capture microdissection coupled with LC/MS analysis to spatially-quantify drug distributions within pulmonary tuberculosis granulomas. The approach has broad applicability to quantifying drug concentrations within tissues at high spatial detail.

Spatial Quantification of Drugs in Pulmonary Tuberculosis Lesions by Laser Capture Microdissection Liquid Chromatography Mass Spectrometry (LCM-LC/MS)

Here we describe a single-cell proteomic approach to evaluate immune phenotypic and functional (intracellular cytokine induction) alterations in peripheral whole blood samples, analyzed via mass cytometry.

Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry

Current methods of analyzing patients’ adherence to complex drug resistant-tuberculosis (DR-TB) regimens can be inaccurate and resource-intensive. Our method analyzes hair, an easily collected and stored matrix, for concentrations of 11 DR-TB medications. Using LC-MS/MS, we can determine sub-nanogram drug levels that can be utilized to better understand drug adherence.

Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples

A reliable and repeatable way to produce a cervical unilateral spinal cord injury using the Infinite Horizon impactor is described. The method takes advantage of a custom designed frame and clamp to stabilize the spine.  The standardized procedure and biomechanical injury parameters result in sufficient and sustained injuries.

A Contusive Model of Unilateral Cervical Spinal Cord Injury Using the Infinite Horizon Impactor

To unravel the earliest molecular mechanisms underlying prostate cancer initiation, novel and innovative human model systems and approaches are desperately needed.  The potential of pre-prostatic urogenital sinus mesenchyme (UGSM) to induce pluripotent stem cell populations to form human prostate epithelium is a powerful experimental tool in prostate research.

Formation of Human Prostate Epithelium Using Tissue Recombination of Rodent Urogenital Sinus Mesenchyme and Human Stem Cells

Learn to quantify tacrolimus in dried blood spots using HPLC-MS/MS for therapeutic drug monitoring. This minimally invasive method enables patient self-collection and supports accurate immunosuppressant analysis.

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Explore More Videos